Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
During the past 3 years, the average EBITDA Per Share Growth Rate was 57.40% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was -16.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 6 years, the highest 3-Year average EBITDA Per Share Growth Rate of Cardio Diagnostics Holdings was 57.40% per year. The lowest was -68.00% per year. And the median was -24.20% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Cardio Diagnostics Holdings 3-Year EBITDA Growth Rate Related Terms
CDIO vs ERNA, LABT, JAGX: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Cardio Diagnostics Holdings's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cardio Diagnostics Holdings 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cardio Diagnostics Holdings's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Cardio Diagnostics Holdings's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 57.40% mean?
Cardio Diagnostics Holdings (CDIO) has a 3-Year EBITDA Growth Rate of 57.40% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Cardio Diagnostics Holdings and its competitors. According to the industry distribution chart, Cardio Diagnostics Holdings ranks #122 out of 1136 companies in the Biotechnology industry, placing it in the top 10.7%.
Is Cardio Diagnostics Holdings' 3-Year EBITDA Growth Rate too high?
Cardio Diagnostics Holdings' current 3-Year EBITDA Growth Rate is 57.40%. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.95. Cardio Diagnostics Holdings' value of 57.40% is 283.9% above this industry median. Based on the distribution chart, Cardio Diagnostics Holdings ranks #122 out of 1136 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Cardio Diagnostics Holdings has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cardio Diagnostics Holdings' 3-Year EBITDA Growth Rate compare to ERNA and LABT?
According to the Biotechnology industry distribution chart, Cardio Diagnostics Holdings ranks #122 out of 1136 companies for 3-Year EBITDA Growth Rate. This places Cardio Diagnostics Holdings in the top 11% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 14.95. Cardio Diagnostics Holdings' value of 57.40% is 283.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.95, based on 1,136 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cardio Diagnostics Holdings's current 3-Year EBITDA Growth Rate of 57.40% is 283.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Cardio Diagnostics Holdings and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cardio Diagnostics Holdings's current 3-Year EBITDA Growth Rate is 57.40%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cardio Diagnostics Holdings stock overvalued right now?
Based on GuruFocus' analysis, Cardio Diagnostics Holdings (CDIO) is currently considered Possible Value Trap. The stock's GF Value™ is $2.77, compared to a current price of $1.56 — trading 43.7% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 57.40% and 283.9% above the Biotechnology industry median of 14.95. Cardio Diagnostics Holdings' overall GF Score™ is 49/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Cardio Diagnostics Holdings (CDIO), the current 3-Year EBITDA Growth Rate is 57.40% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cardio Diagnostics Holdings (CDIO) Overvalued in 2026?
Based on GuruFocus' analysis, Cardio Diagnostics Holdings stock appears to be undervalued.
The current stock price of $1.56 is trading 43.7% below its estimated GF Value™ of $2.77.
GuruFocus considers Cardio Diagnostics Holdings to be Possible Value Trap.
Key valuation signals for CDIO:
3-Year EBITDA Growth Rate: 57.40%
GF Value™: $2.77 vs. price of $1.56 (43.7% below fair value)
Industry Position: 283.9% above the Biotechnology median (#122 of 1136)
No single metric tells the full story. See the CDIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases and associated comorbidities by leveraging its Artificial Intelligence (AI)-driven Multi-Omics Engine. The company has developed two clinical products: Epi+Gen CHD and PrecisionCHD, epigenetics-based clinical blood tests capable of assessing risk for a coronary heart disease (CHD) event, including heart attacks. Additionally, its portfolio includes HeartRisk, a cardiovascular disease risk intelligence platform, and CardioInnovate360, a research-use-only solution launched to support the discovery, development, and validation of novel biopharmaceuticals for the assessment and management of cardiovascular diseases.
49GF Score
Get the complete analysis for CDIO
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CDIO has been successfully added to your 
